share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Matthew Richard

SEC announcement ·  May 3 16:33
Summary by Moomoo AI
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of 4,681 shares of common stock on 05/02/2024. The shares were sold at a price of $8.7378 per share, resulting in a total transaction value of $40,901.64. This transaction followed an acquisition of 4,166 shares on 05/01/2024, which were granted at no cost. After these transactions, Moore holds a total of 145,505 shares in the company. The sale took place in the open market and is part of the normal course of insider transactions.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of 4,681 shares of common stock on 05/02/2024. The shares were sold at a price of $8.7378 per share, resulting in a total transaction value of $40,901.64. This transaction followed an acquisition of 4,166 shares on 05/01/2024, which were granted at no cost. After these transactions, Moore holds a total of 145,505 shares in the company. The sale took place in the open market and is part of the normal course of insider transactions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more